11 January 2023

The future of breast cancer surgery is coming – with the help of funding from the Portuguese PRR

The name of the project is “MetaBreast - Metaverse for Breast Cancer Surgery”. Developed specifically in the field of breast cancer, it may one day also be applicable in other surgical contexts. For now, its goal is to “develop and test a new medical device to visualize malignant tissue in real time inside the patient’s breast and within the operating room”, states the document presenting the project. One of MetaBreast’s participants is the Champalimaud Foundation’s (CF) Breast Unit, represented by breast cancer surgeon Pedro Gouveia.  

22 December 2022

10+ years already?!?!

To directly jump to the memories and testimonials - click here.

To get some historical (and personal) perspective, keep reading.

 

29 November 2022

Not all movement disorders are equal, but early diagnosis can help fight them all

To mark this date, we asked Marcelo Mendonça, neurologist and researcher from the Neuropsychiatry Unit and Neural Circuits Dysfunction Lab at the Champalimaud Foundation to provide an overview of Movement Disorders, their symptoms, diagnosis and treatments.

04 November 2022

Work from Champalimaud Foundation Researcher Acknowledged by the Eppendorf & Science Prize for Neurobiology

After receiving her bachelor's degree in Biochemistry and a master's degree in Health Sciences from the University of Minho, which introduced her to the field of immunology, Cardoso embarked upon a PhD in the laboratory of Henrique Veiga-Fernandes at the Champalimaud Foundation to study the role of neuro-immune interactions in metabolism.

03 November 2022

Searching for the fine details of the complex interplay between cancer, metastases and their environment

Everything around a malignant tumour and its metastases, from its so-called microenvironment to the patients themselves as individuals, influences cancerous growth, and ultimately the outcome of the disease. This is the take-away message from CRSy2022 – the three-day international scientific symposium that took place at the Champalimaud Foundation, in Lisbon, from 19 to 21 October.

06 October 2022

The multiple dimensions of the first European Researchers' Night at the Champalimaud Foundation

This public event, organised by the RAISE (Researchers in Action for Inclusion in Science and Education) consortium composed of the NGO Native Scientist, the Champalimaud Foundation and the Instituto de Medicina Molecular João Lobo Antunes (iMM), joined the 49 ERNs that took place in 25 European countries on the same date.

27 September 2022

The Champalimaud Foundation will host the Neuro, Digital & AI Innovation Summit

Organised by Broadreach Global with the European Brain Foundation (EBC), this summit will  bring together - in a collaborative, roundtable format - a highly diverse group of key opinion leaders, from  innovators, to decision-makers. 

26 September 2022

Female flies enter the ring of sexual competition

When it comes to sexual competition, males have the star role. Clashing bodies, locking horns, biting and kicking are all considered fair play. Since these behaviours are so salient and robust, most studies focus on male behaviour, leaving females aside. 
 

20 September 2022

Concurso CaixaResearch announces funding awardees: Leopoldo Petreanu among winners

The CaixaResearch Health Research Contest 2022 has selected 33 promising new biomedical and health projects promoted by research centres and universities in Spain and Portugal. Once again affirming that the “la Caixa” Foundation, in collaboration with BPI, supports projects of excellence that can have a positive impact on the health of citizens. 

Within this framework, it has allocated a total of 23.1 million euros to such projects – 20 Spanish and 13 Portuguese – that will be developed over the next three years. 

09 September 2022

Champalimaud Foundation researchers discover new tool for improving pancreatic cancer care

The statistics for pancreatic cancer are sobering. With a five-year survival rate of only 9%, incidence of the most common type, pancreatic ductal adenocarcinoma (PDAC), is growing and projected to be the second cause of cancer deaths by 2030. Surgery remains the most effective treatment, yet for 70-80% of patients, surgery is not a viable option. Understanding pancreatic cancer at the cellular and subcellular level is essential for developing therapies that can buy patients more time.
 

Subscribe to Champalimaud Research
Loading
Please wait...